NCT06393309Completed
Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy
Investigation of Long-term Outcome of Levetiracetam and Valproate in Treatment of Idiopathic Generalized Epilepsy
Source: ClinicalTrials.gov · Last updated 2 May 2024
Brief summary (registry, in English)
This study aimed to compare the long-term efficacy and safety of levetiracetam and valproate in treatment of idiopathic generalized epilepsy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 169 (actual)
- First submitted
- 26 Apr 2024
- Start date
- 3 Sept 2022
- Primary completion date
- 19 Mar 2024
- Lead sponsor
- Mazandaran University of Medical Sciences
- Diseases
- Epilepsy
- NCT number
- NCT06393309
What you commit to
- Study type: Observational
- Participants enrolled: 169
- From 3 Sept 2022 to the primary completion date, 19 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Poor drug adherence
Other
- Pregnancy
Who the study is looking for
- Diagnosis of juvenile myoclonic epilepsy or generalized tonic-clonic seizure alone
- Regular monotherapy with levetiracetam or sodium valproate
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bu Ali Sina Hospital Coordinator of this site? Confirm its status | Sari | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.